Opening clinical trial data: are the voluntary data-sharing portals enough?

BMC Medicine

Atul J. Butte²  Sanchita Bhattacharya²  Jennifer Bollyky¹  Nophar Geifman² 

[1] Sean N. Parker Center for Allergy Research, Department of Pediatrics, Division of Allergy, Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA, USA;Institute for Computational Health Sciences, University of California San Francisco, Mission Hall, 550 16th Street, 4th Floor, San Francisco 94158-2549, CA, USA

关键词: Reanalysis;    Open access;    Meta-analysis;    Clinical trials;    Clinical data;   

Others  :  1233462
DOI  :  10.1186/s12916-015-0525-y

 received in 2015-09-30, accepted in 2015-11-03,  发布年份 2015

【 摘 要 】

Data generated by the numerous clinical trials conducted annually worldwide have the potential to be extremely beneficial to the scientific and patient communities. This potential is well recognized and efforts are being made to encourage the release of raw patient-level data from these trials to the public. The issue of sharing clinical trial data has recently gained attention, with many agreeing that this type of data should be made available for research in a timely manner. The availability of clinical trial data is most important for study reproducibility, meta-analyses, and improvement of study design. There is much discussion in the community over key data sharing issues, including the risks this practice holds. However, one aspect that remains to be adequately addressed is that of the accessibility, quality, and usability of the data being shared. Herein, experiences with the two current major platforms used to store and disseminate clinical trial data are described, discussing the issues encountered and suggesting possible solutions.

【 授权许可】

   
2015 Geifman et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Sharing clinical trial data: maximizing benefits, minimizing risk. The National Academies Press, Washington, DC; 2015.
• [2]Rosenblatt M, Jain SH, Cahill M. Sharing of clinical trial data: benefits, risks, and uniform principles. Ann Intern Med. 2015; 162(4):306-7.
• [3]Nisen P, Rockhold F. Access to patient-level data from GlaxoSmithKline clinical trials. N Engl J Med. 2013; 369(5):475-8.
• [4]Hede K. Project data sphere to make cancer clinical trial data publicly available. J Natl Cancer Inst. 2013; 105(16):1159-60.
• [5]Bhattacharya S, Andorf S, Gomes L, Dunn P, Schaefer H, Pontius J et al.. ImmPort: disseminating data to the public for the future of immunology. Immunol Res. 2014; 58(2–3):234-9.
• [6]Milne CP, Bruss JB. The economics of pediatric formulation development for off-patent drugs. Clin Ther. 2008; 30(11):2133-45.